We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqCM - Delayed Quote USD

IceCure Medical Ltd (ICCM)

0.7600

+0.0020

(+0.26%)

At close: June 10 at 4:00 PM EDT

Key Events

Loading Chart for ICCM

9/21 12:03 PM

DELL

Previous Close 0.7580
Open 0.7848
Bid 0.7486 x 100
Ask 0.7705 x 100
Day's Range 0.7580 - 0.7848
52 Week Range 0.5200 - 1.5700
Volume 155,279
Avg. Volume 421,995
Market Cap (intraday) 36.434M
Beta (5Y Monthly) 3.00
PE Ratio (TTM) --
EPS (TTM) -0.3200
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 3.33

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

www.icecure-medical.com

71

Full Time Employees

December 31

Fiscal Year Ends

Sector

Medical Devices

Industry

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

Best website creation site | Build your store in minutes

Best website creation site | Build your store in minutes

Create your website and grow with confidence. From an intuitive website builder to advanced business solutions & powerful SEO tools—Try Shopify

Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ICCM

28.97%

S&P 500

12.39%

1-Year Return

ICCM

36.67%

S&P 500

24.70%

3-Year Return

ICCM

93.60%

S&P 500

19.93%

5-Year Return

ICCM

93.60%

S&P 500

19.93%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

IceCure Medical Ltd

0.7600

+0.26%

Mkt Cap 36.434M

Industry Medical Devices

6.66

+3.42%

Mkt Cap 110.987M

Industry Medical Devices

Xylo Technologies Ltd.

1.8300

+7.02%

Mkt Cap 3.467M

Industry Medical Devices

Inspira Technologies Oxy B.H.N. Ltd.

2.0200

-2.88%

Mkt Cap 35.097M

Industry Medical Devices

Tenon Medical, Inc.

0.6440

-2.75%

Mkt Cap 2.402M

Industry Medical Devices

Bluejay Diagnostics, Inc.

0.5001

+15.50%

Mkt Cap 1.453M

Industry Medical Devices

Modular Medical, Inc.

1.6500

+4.10%

Mkt Cap 51.133M

Industry Medical Devices

0.1480

+2.07%

Mkt Cap 4.942M

Industry Medical Devices

Motus GI Holdings, Inc.

0.0784

-25.33%

Mkt Cap 452,280

Industry Medical Devices

Sintx Technologies, Inc.

4.5500

-11.65%

Mkt Cap 2.791M

Industry Medical Devices

Vivos Therapeutics, Inc.

2.4700

+0.82%

Mkt Cap 7.971M

Industry Medical Devices

Valuation Measures

    Annual 

As of 6/10/2024

Market Cap

36.34M
Enterprise Value

25.93M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

10.67
Price/Book (mrq)

3.12
Enterprise Value/Revenue

7.95
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-41.78%
Return on Equity (ttm)

-77.97%
Revenue (ttm)

3.23M
Net Income Avi to Common (ttm)

-14.65M
Diluted EPS (ttm)

-0.3200

Balance Sheet and Cash Flow

Total Cash (mrq)

11.06M
Total Debt/Equity (mrq)

4.93%
Levered Free Cash Flow (ttm)

-7.75M

Analyst Price Targets

2.90

3.33 Average

0.7600 Current

4.41 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Earnings

Consensus EPS

ICCM does not have Company Insights

SPRC SciSparc Ltd.

0.9000

-0.29%

PXMD PaxMedica, Inc.

0.2940

-5.77%

CDIO Cardio Diagnostics Holdings, Inc.

0.6200

-8.47%

HSCS Heart Test Laboratories, Inc.

5.65

0.00%

INAB IN8bio, Inc.

1.3100

-2.24%

PALI Palisade Bio, Inc.

4.6100

+0.88%

CMND Clearmind Medicine Inc.

1.0200

-0.97%

KPRX Kiora Pharmaceuticals, Inc.

0.4620

-1.70%

HUBC HUB Cyber Security Ltd.

0.7510

+0.13%

ILAG Intelligent Living Application Group Inc.

0.4048

+4.17%

FRGT Freight Technologies, Inc.

0.6000

-2.45%

WLDS Wearable Devices Ltd.

0.4110

+21.60%

SNTI Senti Biosciences, Inc.

0.2602

-7.27%

QNRX Quoin Pharmaceuticals, Ltd.

0.7400

+2.76%

FEMY Femasys Inc.

1.0900

+4.81%

VS Versus Systems Inc.

1.7700

-1.12%